Basilea Pharmaceutica AG: Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update
Continued commercial success of Cresemba and Zevtera in 2022 generated revenue contributions of approx. CHF 122 million, exceeding guidance by more than 17%Significant proceeds from oncology transactionsFollowing